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Abstract
A key issue in cancer biology is whether oncogenic transformation of different cell types of origin 
within an adult tissue gives rise to distinct tumor subtypes that differ in their prognosis and/or 
treatment response. We now show that initiation of prostate tumors in basal or luminal epithelial 
cells in mouse models results in tumors with distinct molecular signatures that are predictive of 
human patient outcomes. Furthermore, our analysis of untransformed basal cells reveals an 
unexpected assay-dependence of their stem cell properties in sphere formation and transplantation 
assays versus genetic lineage-tracing during prostate regeneration and adult tissue homeostasis. 
Although oncogenic transformation of basal cells gives rise to tumors with luminal phenotypes, 
cross-species bioinformatic analyses indicate that luminal origin tumors are more aggressive than 
basal origin tumors, and identify a molecular signature associated with patient outcome. Our 
results reveal the inherent plasticity of basal cells, and support a model in which different cells of 
origin generate distinct molecular subtypes of prostate cancer.
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
*Author for correspondence at: phone: (212) 851-4723; fax: (212) 851-4572; mshen@columbia.edu. 
Author contributions
Z.A.W. carried out mouse experiments, Z.A.W. and S.K.B. performed transplantation experiments, A.M. performed bioinformatic 
analyses, and R.D.C. analyzed tumor histology. Z.A.W. and M.M.S. designed the overall study, C.A.-S., R.D.C., A.C., and M.M.S. 
supervised the data analysis, and Z.A.W., A.M., and M.M.S. wrote the manuscript, in consultation with C.A.-S. and A.C. All authors 
provided discussion and comments on the manuscript.
HHS Public Access
Author manuscript
Nat Cell Biol. Author manuscript; available in PMC 2013 September 01.
Published in final edited form as:
Nat Cell Biol. 2013 March ; 15(3): 274–283. doi:10.1038/ncb2697.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The analysis of tumor cell of origin requires a detailed understanding of tissue cell types and 
their position in the lineage hierarchy1. In particular, stem cells are often considered to be 
excellent candidate cells of origin for cancer, given their inherent ability to self-renew. In 
the prostate gland, the three epithelial cell types are luminal cells, which express 
cytokeratins (CK) 8 and 18, and high levels of androgen receptor, basal cells, which express 
p63, CK5, and CK14, and rare neuroendocrine cells; in addition, a minor basal 
subpopulation known as “intermediate cells” co-express basal and luminal markers2. 
Notably, the adult prostate can undergo cycles of regression and regeneration following 
androgen ablation and restoration, implying that the prostate epithelium contains stem cells 
that function to promote regeneration.
To date, prostate stem cell populations have been identified in both the basal and luminal 
layers3–7. In particular, subpopulations of basal cells isolated using cell-surface markers 
display multipotency and self-renewal in sphere formation as well as tissue reconstitution 
assays8–13. Other work has identified a rare luminal population of castration-resistant 
Nkx3.1-expressing cells (CARNs) that displays stem cell properties in genetic lineage-
tracing and tissue reconstitution assays14. It has been unclear whether these findings are 
mutually consistent, given the distinct assays for stem cell properties that have been 
employed.
The cell of origin model for intertumor heterogeneity proposes that tumor initiation from 
distinct cell types in the lineage hierarchy gives rise to tumor subtypes with different 
prognoses and/or treatment responses1, 15. Although this model has received considerable 
support in studies of breast cancer16, it has not been systematically investigated in prostate 
cancer. However, several groups have investigated whether luminal cells or basal cells, or 
both, might serve as cell types of origin for prostate cancer. In particular, lineage-tracing 
analyses of CARNs have provided evidence that rare luminal cells can act as a cell of origin 
in vivo14, while other studies have shown that lentiviral overexpression of oncogenes in 
isolated mouse and human basal cells can give rise to tumors with luminal phenotypes in 
renal grafts, whereas luminal cells fail to generate tumors under these conditions13, 17. In 
addition, a recent study has shown that both luminal and basal cells can serve as cells of 
origin for prostate cancer, generating tumors that are histologically similar in mouse 
models18.
These previous studies have raised the possibility that ex vivo cell culture and tissue grafting 
assays may yield different results from in vivo lineage-tracing analyses. Therefore, we have 
undertaken a comprehensive analysis of prostate basal cell properties using genetic lineage-
marking to examine the properties of the identical cell population in multiple assays for stem 
cell function. Our results show that apparent discrepancies in the published literature can be 
explained by the considerable plasticity of basal cells in distinct functional assays. 
Moreover, although both basal and luminal cells can serve as cells of origin for prostate 
cancer, giving rise to tumors with similar histological phenotypes, our molecular and 
bioinformatic analysis shows that the luminal origin tumors are more aggressive, and 
identifies a molecular signature that has predictive value for human patient survival. Thus, 
our study supports the cell of origin model as a basis for distinct prostate cancer subtypes.
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Results
Analysis of lineage-marked prostate basal cells in cell culture and grafting assays
To provide a comprehensive analysis, we have performed genetic marking of prostate 
epithelial basal cells using a CK5-CreERT2 transgenic line19 in combination with the R26R-
YFP reporter allele20 for isolation of a purified cell population for sphere formation and 
tissue reconstitution assays and for lineage-tracing in vivo. In control experiments, 
tamoxifen induction of hormonally-intact CK5-CreERT2; R26R-YFP/+ mice resulted in 
highly-specific expression of YFP in 24.5% (n=1,538/6,267) of CK5-positive basal cells in 
the anterior prostate lobe, while no YFP-positivity was observed in non-basal cells 
(n=0/15,846) (Fig. 1a); quantitation for all experiments is detailed in Supplementary Table 
S1. We verified that the YFP-marked cells were positive for the basal cell marker p63 and 
CK14, and were mostly negative for the luminal marker CK18 (Supplementary Fig. S1a,e–
n), and were detected at similar frequencies in the dorsolateral (23.2%) and ventral (24.9%) 
prostate lobes (Supplementary Fig. S1c,d). Furthermore, 1.6% of p63+YFP+ cells also 
expressed the luminal marker CK18 (Supplementary Fig. S1o–s), indicating that the marked 
population includes intermediate cells.
Next, we isolated lineage-marked YFP-positive cells by flow-sorting of dissociated prostate 
cells from tamoxifen-induced CK5-CreERT2; R26R-YFP/+ mice. Approximately 3.2% of 
total prostate cells were isolated in the YFP+ fraction (Fig. 1b), and greater than 98% of 
these isolated YFP+ cells were CK5-positive, p63-positive, and CK18-negative 
(Supplementary Fig. S2a–l). Furthermore, we compared this YFP+ population to that of 
Lin−Sca-1+CD49fhi (LSC) cells, which have been previously characterized as a basal 
population enriched for stem/progenitor cells8, 12. Nearly all YFP+ cells (98.7%) were 
contained in the Lin−CD49f+ population, and 8.0% of the YFP+ cells were present in the 
Lin−Sca-1+CD49fhi fraction (Fig. 1c). Conversely, we found that 24.4% of the 
Lin−Sca-1+CD49fhi cells from tamoxifen-induced CK5-CreERT2; R26R-YFP/+ mice were 
YFP+ (Fig. 1d,e), similar to the overall percentage of YFP+ basal cells. These results 
indicate that the YFP+ population includes Lin−Sca-1+CD49fhi cells in a proportional and 
unbiased manner.
Using unsorted dissociated cells from tamoxifen-induced CK5-CreERT2; R26R-YFP/+ 
prostate tissue in sphere formation assays, we found that approximately 23% of the resulting 
spheres were YFP-positive (Fig. 1f), consistent with the overall percentage of marked basal 
cells. After flow-sorting, 4.7% of the YFP-positive cells could form spheres that displayed 
expression of basal and luminal markers (Fig. 1g; Supplementary Fig. S2m–r), consistent 
with previous studies8, 21. This frequency of sphere formation was similar between the 
Lin−Sca-1+CD49fhi YFP-positive cells and the remaining YFP-positive cells 
(Supplementary Fig. S2s), and was similar in mice at both 2 months and 12 months of age 
(Fig. 1g).
Tissue reconstitution assays have been used to show that Lin−Sca-1+CD49f+ and 
Lin−Sca-1+CD49fhiTrop2hi cells readily generate prostate ducts in renal grafts8, 12, but the 
overall efficiency of basal cells in this assay has not been previously determined. Therefore, 
we have used our highly purified YFP+ population in prostate reconstitution assays, and 
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have performed a limiting dilution analysis to determine the percentage of basal cells with 
reconstituting ability. This analysis shows that approximately 3.9% of basal cells contain 
graft-forming activity (Fig. 1h,i), which display their donor origin by expression of YFP, 
prostatic histology, and the formation of ducts with luminal, basal, and neuroendocrine cells 
(Fig. 1j–o; Supplementary Fig. S2t). Notably, the similar efficiencies of tissue reconstitution 
(3.9%) and sphere formation (4.7%) raises the possibility that these two distinct assays may 
identify the same progenitor population.
Identification of rare bipotential basal cells during prostate regeneration in vivo
Using lineage-tracing, we explored the properties of basal cells during prostate regeneration 
in vivo, using a protocol similar to one that we have previously employed14. We marked 
prostate basal cells by tamoxifen treatment of hormonally-intact CK5-CreERT2; R26R-
YFP/+ mice, as in Fig. 1a, followed by androgen-deprivation to induce prostate regression, 
and then androgen restoration to promote prostate regeneration (Fig. 2a). After regeneration, 
we found that most YFP+ cells were basal, but 0.04% of YFP+ cells were luminal 
(n=5/11,427 cells) (Fig. 2b–f; Supplementary Table S1). Notably, the percentage of basal 
cells displaying bipotentiality as detected by lineage-tracing in vivo is significantly lower 
than the percentage displaying stem cell properties in sphere formation or tissue 
reconstitution assays (p<0.0001; χ2 test).
We next asked whether this low detection rate of marked luminal cells might reflect an 
inherently low proliferation rate of basal cells (Fig. 2g,h; Supplementary Fig. S3). Using 
both Ki67 immunostaining and BrdU incorporation methods, we found that approximately 
8.0% of basal cells proliferated during prostate regeneration (Fig. 2g,h; Supplementary Fig. 
S3). Furthermore, rare bipotential basal cells were observed at approximately 0.05% 
frequency using alternative regeneration protocols or in aged mice (Supplementary Fig. S4). 
Taken together, these results indicate that the frequency of luminal cell generation by 
dividing basal cells is low but stable during regeneration in vivo (Supplementary Table S1).
Given these findings, we then investigated whether lineage-marked luminal progeny of basal 
cells would accumulate during serial rounds of androgen-deprivation and androgen-
restoration to drive prostate regression and regeneration. We analyzed the frequency of 
YFP+ luminal cells among total YFP+ cells after three and five rounds of serial regeneration, 
as well as after four rounds in the regressed state (Fig. 2i–o). We observed 0.6% marked 
luminal cells after three rounds and 3.4% after five rounds (Fig. 2j–l,n,o). Thus, there is a 
gradual increase in the percentage of luminal cells among YFP+ cells with increasing rounds 
of regeneration, which is further supported by the detection of castration-resistant YFP+ 
luminal cells in the regressed prostate after four rounds (Fig. 2m). Taken together, these 
results are consistent with a model in which a bipotential basal progenitor can give rise to 
luminal progeny with transit-amplifying characteristics.
Identification of rare bipotential basal cells during prostate homeostasis in vivo
We also examined the generation of luminal cells by lineage-marked basal cells during 
prostate homeostasis, using tamoxifen induction at 2 months of age followed by a long chase 
period (Fig. 3a). Similar to our analysis of serial regeneration, we found that the frequency 
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of YFP+ luminal cells among all YFP+ cells increased with time, as determined at 4 months 
(0.02%), 6 months (0.5%), or 12 months (3.0%) of age (Fig. 3b–f). However, using BrdU 
incorporation assays, we found that the proliferation rate in both basal (1.1%) and luminal 
(6.1%) compartments was relatively stable at 2, 6, and 12 months of age (Fig. 3g–n). These 
results suggest that low-frequency generation of luminal cells from a bipotential basal 
progenitor results in small clusters of lineage-marked luminal cells, due to the higher 
proliferation rate of luminal cells during homeostasis. Furthermore, these findings indicate 
that basal cells display bipotentiality during regeneration and tissue homeostasis at 
approximately similar frequencies.
Basal cells as a cell of origin for prostate cancer
Next, we investigated whether CK5+ basal cells can be a cell of origin for prostate cancer, 
using a conditional allele of the Pten tumor suppressor for inducible inactivation in mice, 
modeling one of the most frequent genetic alterations in human prostate cancer22, 23. We 
found that CK5-CreERT2; Ptenflox/flox; R26R-YFP/+ prostates at 1 month following 
tamoxifen induction displayed small foci of epithelial hyperplasia and Grade I PIN lesions24 
in otherwise histologically normal glands (Fig. 4a,b; Supplementary Table S2). At this stage, 
we could detect phosphorylated Akt in basal cells, as expected after loss of Pten (Fig. 4f). 
By 3 months after induction, these mice displayed Grade II and III PIN lesions, while at 6 
months they had Grade III and IV lesions (Fig. 4c,d; Supplementary Fig. S5; Supplementary 
Table S2). Interestingly, we observed increased cell proliferation in basal cells prior to PIN 
lesion formation (Fig. 4g; Supplementary Table S2), and subsequently in the PIN/tumor 
lesions (Fig. 4h). Notably, even small PIN lesions contained few CK5+ basal cells (Fig. 
4i,m), but instead were mostly comprised of CK18+ and AR+ luminal cells (Fig. 4j,k,m), 
indicating that oncogenic transformation of basal cells promotes luminal differentiation of 
their progeny. Furthermore, the low frequency of CK5+CK18+ intermediate cells in the 
untransformed prostate (1.6%; Supplementary Fig. 1o–s) and during tumor formation (3.0%; 
Fig. 4l,m) suggests that luminal differentiation occurs from transformed basal cells, and does 
not arise exclusively from intermediate cells.
We next examined whether the time course and histopathology of PIN/tumor lesions in 
CK5-CreERT2; Ptenflox/flox; R26R-YFP/+ mice differed from those in Nkx3.1CreERT2/+; 
Ptenflox/flox; R26R-YFP/+ mice (Fig. 4e; Supplementary Fig. S6a–n), which have a luminal 
cell of origin. Consistent with a recent report18, we found that the overall histopathology of 
the luminal origin PIN/tumor lesions was very similar, but arose with a different time 
course. At 1 month after induction, the Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ mice 
displayed Grade II and III PIN, resembling 3-month basal origin lesions (Fig. 4c; 
Supplementary Fig. S6b; Supplementary Table S2). Similarly, 3-month luminal origin 
tumors displayed Grade III and IV PIN, resembling 6-month basal origin tumors (Fig. 4d,e; 
Supplementary Fig. S6c,d; Supplementary Table S2). These histopathological similarities 
were further supported by marker analyses (Fig. 4h–k; Supplementary Fig. S6f–k). 
However, we did note that CK5+CK18+ cells occurred at low frequencies in all prostate 
lobes of basal origin lesions, but at higher frequencies in the anterior and dorsolateral lobes 
of luminal origin lesions (Fig. 4l,m; Supplemental Fig. S6l–n). Overall, basal origin tumors 
are histologically similar to luminal origin tumors, but arise more slowly, perhaps due to 
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differences in the starting number of cells undergoing transformation and/or an intrinsic 
delay due to luminal differentiation from basal cells.
A luminal origin molecular signature predicts patient survival
To determine whether basal and luminal origin tumors might display molecular differences, 
we performed transcriptome analyses comparing PIN/tumor lesions from basal or luminal 
origins at time points at which they displayed similar histopathological phenotypes. We used 
RNA-seq to profile prostate tissue from basal origin tumors of CK5-CreERT2; Ptenflox/flox; 
R26R-YFP/+ mice that were uninduced (control), or at 3 or 6 months after tamoxifen 
induction, or from luminal origin tumors of Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ 
mice that were uninduced (control), or at 1 or 3 months after induction (6 mice/category). 
Principal Components Analysis demonstrated the reproducibility of the independent 
biological replicates (Fig. 5a,b). We then performed Gene Set Enrichment Analysis (GSEA) 
to compare “initiation” signatures for basal origin lesions (3 months vs. control) and for 
luminal origin lesions (1 month vs. control) (Supplementary Tables S3, S4); a similar 
comparison was performed for “progression” signatures for basal origin (6 months vs. 3 
months) and luminal origin lesions (3 months vs. 1 month) (Supplementary Tables S5, S6). 
These comparisons demonstrated the strong reciprocal enrichment of the “initiation” as well 
as “progression” signatures (Fig. 5c,d), indicating that basal and luminal origin tumors are 
globally similar at the molecular level.
Nonetheless, we could identify molecular differences between the luminal and basal origin 
signatures by applying bioinformatic subtraction of the similar components of their 
signatures. Thus, we generated a mouse expression signature containing genes up-regulated 
in luminal origin lesions relative to basal origin lesions (luminal 3 months – basal 6 months), 
or conversely up-regulated in basal origin lesions (Supplementary Table S7). Next, we used 
a mouse-to-human cross species approach to compare this mouse luminal vs. basal signature 
to a human “lethality signature” generated using survival data in a Swedish “watchful-
waiting” patient cohort25. We defined this lethality signature as a list of genes ranked by 
their differential expression between high-risk (death within 12 months, 6 samples) and low-
risk (survival for more than 192 months, 12 samples) cases in this cohort (Supplementary 
Table S8). Using GSEA, we found that genes over-expressed in luminal origin tumors were 
significantly enriched in genes up-regulated in the lethality (high-risk) signature (Fig. 5e). In 
contrast, genes over-expressed in the basal origin tumors displayed no statistical enrichment 
in the human lethality signature (Fig. 5f), suggesting that luminal origin prostate cancer is 
more aggressive than basal origin prostate cancer. Furthermore, we used the luminal vs. 
basal origin signature to infer Gene Ontology-Biological Process (GO-BP) gene sets that 
were significantly up- or down-regulated. We identified 57 such GO-BP categories (p<0.05) 
(Fig. 5g; Supplementary Table S9), including categories such as “cell cycle mitotic”, “E2F–
mediated regulation of DNA replication”, and “extension of telomeres”, consistent with a 
more aggressive phenotype of luminal origin tumors.
Next, we investigated the clinical relevance of the 68 genes with significant contribution to 
the enrichment of the luminal origin up-regulated signature in the human lethality signature 
(the “leading edge” in Fig. 5e; Supplementary Table S10). Interestingly, many of these 68 
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genes are up-regulated in human prostate cancer, as shown by analysis of five human patient 
datasets22, 26–29 (Supplementary Fig. S6o; Supplementary Table S10). We tested this 
luminal origin leading-edge signature (LOLES) with two different datasets from Memorial 
Sloan-Kettering Cancer Center (MSKCC)22, 30, in which patients are characterized by their 
biochemical recurrence (BCR) free survival time, representing the duration between 
prostatectomy and subsequent detection of rising serum prostate-specific antigen (PSA) 
levels. Using k-means clustering, we could stratify the 79 primary tumor samples from the 
Glinsky dataset30, and the 131 primary tumor samples from the Taylor dataset22, into two 
groups with significant differences in BCR-free survival (log-rank p=0.0255, Fig. 5h; log-
rank p=0.0245, Fig. 5i). Furthermore, the LOLES successfully stratified 263 patients of the 
Swedish cohort (excluding the samples used to define the lethality signature) into two 
distinct groups with a statistically significant difference in mean survival time of 3.4 years at 
50% survival (log-rank p=0.0065, Fig. 5j).
Finally, we examined whether the LOLES may have independent prognostic value 
compared to histological Gleason scoring, which remains the best prognostic marker for 
overall survival31. Indeed, C-statistics analysis using the Swedish watchful-waiting cohort 
revealed that the LOLES improves the prognostic value of Gleason score from 0.76 (C = 
0.76; 95% CI 0.72–0.80, p=1.10e–39) to 0.82 (C=0.82, 95% CI 0.77–0.84, p=2.25e–80) 
(Fig. 5k). Taken together, our bioinformatic analysis shows that the LOLES is highly 
correlated with poor patient prognosis.
Discussion
Using a lineage-marking approach to examine the same population in ex vivo and in vivo 
assays, we have shown that prostate basal cells display distinct properties in different assays 
for stem cell function, and reconcile several aspects of previous work on prostate stem cells 
that have appeared to be discordant. Notably, studies using ex vivo cell culture and tissue 
reconstitution assays have identified prostate basal cells as stem cells8, 12, 21, but our 
analyses indicate that basal cells can exhibit substantial plasticity when removed from their 
endogenous tissue microenvironment. More generally, our work supports the notion that 
genetic lineage-tracing in vivo, not transplantation-based assays, represents a “gold 
standard” for identification of physiologically-relevant stem cells32, and that unexpected 
plasticity should be considered when interpreting the outcomes of other stem cell assays.
In principle, the plasticity of prostate basal cells might be regulated by extrinsic or intrinsic 
factors. For example, stromal and/or luminal cells could inhibit basal cell plasticity, while 
Pten loss might confer independence from this inhibition, allowing formation of transformed 
luminal cells. Moreover, the embryonic urogenital mesenchyme employed in tissue 
reconstitution assays has potent reprogramming activity33, 34, and could perhaps reprogram 
adult prostate basal cells to an embryonic multipotent progenitor state. Another possibility is 
that basal cell plasticity may be intrinsically regulated by cellular proliferation, since the 
percentage of luminal progeny is approximately 1–2% of dividing basal cells during 
regeneration and adult homeostasis. Thus, in response to strong proliferative signals 
provided by embryonic urogenital mesenchyme in tissue reconstitution assays, or due to 
Pten inactivation, basal cells might generate increased numbers of luminal cells.
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Our findings suggest an overall similarity in the functional properties of basal cells in the 
prostate to those in other ductal epithelial tissues. Recent lineage-tracing analyses of the 
mammary and sweat gland epithelium have shown that luminal and myoepithelial cells are 
maintained by distinct unipotent progenitors, while myoepithelial cells can generate luminal 
cells in fad pad transplantation assays35, 36. Our work, together with other recent 
studies18, 37, indicates that a similar lineage relationship exists in the prostate epithelium, 
and that the plasticity of myoepithelial/basal cells may be a conserved attribute of ductal 
epithelial tissues. Moreover, the plasticity of basal cells in the adult prostate epithelium may 
reflect their role as stem/progenitor cells that generate all epithelial cell types during 
organogenesis38, similar to basal progenitors in mammary and sweat gland 
development35, 36.
We have also detected rare prostate basal cells that display bipotentiality during adult tissue 
regeneration and homeostasis, at a frequency similar to that of bipotential luminal CARNs in 
the regressed prostate14. This finding differs from the conclusions of a recent report that the 
prostate basal lineage is completely unipotent18. The basis for this discrepancy is unclear, 
but could be due to the different Cre drivers utilized, or the larger number of cells and 
rounds of regeneration analyzed in this study. Notably, the existence of bipotential adult 
basal stem/progenitor cells is also supported by retrospective lineage analyses of human 
prostate tissue using mitochondrial DNA mutations39, 40. Taken together, our findings 
suggest that basal and luminal lineages are largely independent in the adult prostate, but rare 
basal and luminal stem/progenitor cells can potentially compensate for imbalances in cell 
number during regeneration and tissue homeostasis. One possible model is that rare basal 
(and luminal) stem/progenitor cells may reside at the top of an epithelial lineage hierarchy, 
while a larger subpopulation of basal cells, perhaps corresponding to transit-amplifying 
cells, can display plasticity in sphere and tissue reconstitution assays (Fig. 6a). Alternatively, 
basal cells may display stochastic stem/progenitor properties, with a low probability in the 
adult prostate epithelium and a higher probability when explanted or transformed (Fig. 6b), 
resembling the maintenance of interfollicular and esophageal epithelium by stochastic 
progenitors during homeostasis and wound repair41, 42.
In humans, prostate adenocarcinoma displays a strong luminal phenotype with relatively 
uniform histopathological characteristics, and lacks distinct histological subtypes. At the 
molecular level, there has been some success in classifying tumors on the basis of gene 
expression profiling26, 43, while distinct molecular subtypes may be identifiable by specific 
mutations and/or chromosomal rearrangements22, 23, 44, 45. Nonetheless, prostate cancer has 
previously appeared to differ from other human cancers in which distinct tumor subtypes are 
readily defined16, 46–48. However, although we find that basal and luminal origin tumors in 
mice are histologically similar, as also reported by Choi and colleagues18, our mouse-to-
human cross-species bioinformatic analysis has identified a molecular signature in luminal 
origin tumors that correlates with patient outcome. Thus, our analysis suggests that prostate 
tumors arising from different cell types of origin may have distinct prognostic outcomes 
and/or treatment responses.
A major clinical challenge in prostate cancer research has been to distinguish the minority of 
patients who will develop aggressive disease from those who have indolent cancer and 
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require minimal treatment. Indeed, considerable variation in outcome can exist between 
tumors with identical Gleason scores31, indicating that intertumor heterogeneity exists 
among prostate cancers that are histologically indistinguishable. To date, it has been difficult 
to identify useful prognostic biomarkers to improve upon Gleason scoring, despite 
considerable effort to identify molecular signatures that can successfully stratify aggressive 
from non-aggressive disease25. Our cross-species analyses suggest that the cell of origin 
may represent an important component in determining prostate cancer aggressiveness, and 
may therefore lead to the identification of successful biomarkers.
Methods
Mouse strains and genotyping
The Nkx3.1CreERT2 targeted allele14 and CK5-CreERT2 transgenic line19 have been 
described previously. Genotyping was performed by PCR using tail genomic DNA, with the 
following primer sequences: Nkx3.1 wild-type allele, 5′-CTCCGCTACCCTAAGCATCC-3′ 
and 5′-GACACTGTCATATTACTTGGACC-3′; CreERT2 allele, 5′-
CAGATGGCGCGGCAACACC-3′ and 5′-GCGCGGTCTGGCAGTAAAAAC-3′; Ptenflox 
allele, 5′-ACTCAAGGCAGGGATGAGC-3′ and 5′-GTCATCTTCACTTAGCCATTGG-3′; 
R26R-YFP allele, 5′-GCGAAGAGTTTGTCCTCAACC-3′ (mutated forward), 5′-
GGAGCGGGAGAAATGGATATG-3′ (wild-type forward) and 5′-
AAAGTCGCTCTGAGTTGTTAT-3′ (wild-type and mutated reverse).
Mouse procedures
Castration of adult male mice was performed using standard techniques, with the fully 
regressed state attained at 4 weeks after castration. For prostate regeneration, testosterone 
(Sigma) was dissolved at 25 mg/ml in 100% ethanol and diluted in PEG-400 to a final 
concentration of 7.5 mg/ml. Testosterone was administered for 4 weeks at a rate of 1.875 
µg/h delivered by subcutaneous implantation of mini-osmotic pumps (Alzet). This regimen 
yields physiological levels of serum testosterone49.
For tamoxifen induction, mice were administered 9 mg/40 g tamoxifen (Sigma) suspended 
in corn oil, or vehicle alone for negative controls, by oral gavage once daily for 4 
consecutive days, followed by a chase period of 14 days. BrdU (100 mg/kg) (Sigma) was 
administered by intraperitoneal injection twice daily for 12 consecutive days during 
regeneration or homeostasis to label proliferating cells.
Tissue collection and flow cytometry
For histological and immunofluorescence analysis, individual prostate lobes or renal grafts 
were dissected and fixed in 4% paraformaldehyde for subsequent cryoembedding in OCT 
compound (Sakura), or fixed in 10% formalin followed by paraffin embedding. For RNA 
isolation and RNA-seq analysis, prostate tissues were quickly dissected, flash-frozen in 
liquid nitrogen, and stored at −80°C.
For flow cytometry, prostate tissues were dissected and minced to small clumps, followed 
by enzymatic dissociation with 0.2% collagenase I (Invitrogen) in DMEM media with 5% 
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FBS for 3 h at 37°C. Tissues were digested with 0.25% Trypsin-EDTA (StemCell 
Technologies) for 1 h at 4°C, passed through 21- to 26-gauge syringes and filtered through a 
40-µm cell strainer to obtain single-cell suspensions. Dissociated prostate cells were 
suspended in Hanks’ Balanced Salt Solution Modified/2% FBS. Cell sorting was performed 
on a BD FACS Aria II instrument in the Flow Cytometry Shared Resource of the Herbert 
Irving Comprehensive Cancer Center. Antibodies used for sorting of Lin−Sca-1+CD49fhi 
cells are listed in Supplementary Table S11.
Sphere formation assay
For sphere formation assays, dissociated cells were incubated in PrEGM medium (Lonza). 
For each sample, 40 µl of cell suspension was mixed with 60 µl cold Matrigel, and pipetted 
around the rim of a well of a 12-well plate. The plates were placed in a 37°C CO2 incubator 
for 30 min to allow the Matrigel to solidify. 800 µl warm PrEGM was then added to each 
well. The spheres were cultured and monitored for 7–10 days with 50% medium change 
every 3 days. For sphere differentiation experiments, the spheres were subsequently cultured 
in PrEGM medium with 10−8 M dihydrotestosterone (DHT), and monitored for 6 days with 
50% medium change every 2 days.
Tissue reconstitution assay
For limiting dilution analysis, 5000, 100, or 20 dissociated YFP+ cells obtained from 
tamoxifen-induced CK5-CreERT2; R26R-YFP/+ mice were mixed with 2.5 × 105 dissociated 
urogenital sinus mesenchyme (UGM) cells from embryonic day 18.0 rat embryos. UGM 
cells were obtained from dissected urogenital sinus treated for 30 min in 1% trypsin, 
followed by mechanical dissociation and treatment with 0.1% collagenase B (Roche) for 30 
min at 37°C, and washing in PBS. Pelleted cell mixtures were resuspended in 10 µl of 1:8 
collagen:setting buffer (10× Earle’s Balanced Salt Solution (Life Technologies), 0.2 M 
NaHCO3 and 50 mM NaOH), and gelatinized at 37 °C for 20 min. Tissue recombinants were 
cultured in DMEM/10% FBS supplemented with 10−7 M DHT overnight, followed by 
transplantation under the kidney capsules of immunodeficient NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory). Grafts were collected after 8–12 weeks of 
growth for analysis, and extreme limiting dilution analysis was performed as described50.
Histology and immunostaining
H&E staining was performed using standard protocols on 6 µm paraffin sections. 
Histological assessments were performed using a published classification of mouse PIN 
lesions24.
For immunohistochemical staining, 6 µm paraffin sections were deparaffinized in xylene, 
followed by boiling in antigen unmasking solution (Vector Labs). Slides were blocked in 
10% normal goat serum (NGS) (Vector Labs), and incubated with primary antibodies 
diluted in 10% NGS overnight at 4 °C. Secondary antibodies were obtained from Vectastain 
ABC kits (Vector Labs) and diluted 1:250. Signal was enhanced using the Vectastain ABC 
system and visualized with the NovaRed Substrate Kit (Vector Labs). Slides were 
counterstained with Harris Modified Hematoxylin (1:4 diluted in H2O) (Fisher Scientific) 
and mounted with Clearmount (American MasterTech). H&E and immunohistochemical 
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staining were imaged using a Nikon Eclipse E800 microscope equipped with a Nikon 
DXM1200 digital camera.
Immunofluorescence staining was performed using 6 µm cryosections, which were 
incubated in 3% H2O2 and Antigen Unmasking Solution (Vector Labs), or culture plates for 
whole-mount staining of spheres fixed in 4% paraformaldehyde for 15 min. Samples were 
incubated with 10% NGS and primary antibodies diluted in 10% NGS overnight at 4 °C. 
Samples were then incubated with secondary antibodies (diluted 1:500 in PBST) labeled 
with Alexa Fluor 488, 555, or 647 (Invitrogen/Molecular Probes). Detection of Nkx3.1 was 
enhanced using tyramide amplification (Invitrogen/Molecular Probes) by incubation of 
slides with HRP-conjugated secondary antibody (1:100 dilution) (Invitrogen/Molecular 
Probes), followed by incubation with tyramide 555 for 6 min. Slides were mounted with 
VECTASHIELD mounting medium with DAPI (Vector Labs). Immunofluorescence 
staining was imaged using a Leica TCS SP5 spectral confocal microscope. All primary 
antibodies and dilutions used are listed in Supplementary Table S11.
Cell numbers were counted manually using confocal ×40 and ×63 photomicrographs. 
Statistical analyses were performed using a two-sample t-test, χ2 test, or Fisher’s Exact test 
as appropriate. At least three animals for each experiment or genotype were analyzed.
RNA sequencing
Total RNA from prostate tissues was isolated using the Nucleospin RNA II kit (Clontech). 
The quantity and quality of each sample was measured using an Agilent 2100 Bioanalyzer. 
RNA-seq analysis was performed by the Columbia Genomic Sequencing Core Facility. 
FPKM values for 22,310 genes were reported. Genes with missing values (count of 0) in 
more than 10% of samples were eliminated from the analysis. Missing values for the 
remaining genes were estimated by using impute.knn (impute package in R v2.11.1). The 
resulting dataset of 14,063 genes was normalized by using robust spline normalization 
(RSN) function of R-system v2.11.1 and was log transformed. Principal Components 
Analysis was performed on scaled data, where the data value was adjusted by subtracting its 
mean across all samples and dividing by its standard deviation, z=(x-mean)/std dev. 
Expression data are deposited in the Gene Expression Omnibus database under GSE39509.
Statistical data analysis
Differential expression was estimated using the Welch T-test (t.test function in R v2.11.1). 
To compare two distinct signatures we used Gene Set Enrichment Analysis (GSEA)51, 
where p-value was estimated with 1,000 sample permutations. Fold-change analysis was 
performed on data regenerated by reverse log transformation. Kaplan-Meier curves were 
generated using the surv, survdiff, and survfit functions from package survival in R. C-
statistics analysis was conducted using the concordance index function from the R survcomp 
package. The multivariate Cox proportional hazards model analysis with the Gleason score 
and “leading edge” genes was computed using a multiplicative and additive model for 
defining an integrated risk score model.
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Comparing initiation and progression genes for luminal and basal tumors
To compare genes that are responsible for initiation in tumors of both origins, we compared 
the L1 vs. Lc signature with the B3 vs. Bc signature. The query signature was defined as a 
list of genes ranked by their differential expression in the B3 group (n=5 samples) compared 
to the Bc group (n=6 samples) and was divided into two tails: a positive tail containing top 
200 overexpressed genes in B3 compared to Bc, and a negative tail with top 200 under-
expressed genes in B3 compared to Bc. The target signature was defined between L1 (n=6 
samples) and Lc (n=5 samples) groups (Supplementary Tables S3, S4). Statistical 
significance of the enrichment between the query signatures and the target signatures was 
computed separately for the positive and negative tails using GSEA. Analogous analyses 
were performed comparing L3 vs. L1 with B6 vs. B3 signatures (Supplementary Tables S5, 
S6).
Comparing a luminal vs basal origin mouse signature with a human lethality signature
The luminal versus basal mouse signature (Fig. 5e,f) was defined between L3 (n=6 samples) 
and B6 groups (n=6 samples). For comparison with human prostate cancer expression 
profiling data, mouse genes were mapped to their human orthologs using mouse-human 
orthologous relations from the Mouse Genome Informatics database (MGI, http://
www.informatics.jax.org/). This resulted in reduction of 14,063 mouse genes and 6,144 
human genes to the set of 4,629 genes common between the human and mouse platforms.
The human “lethality risk” signature was derived from the Swedish watchful-waiting 
dataset25, consisting of 281 prostate cancer samples from the cohort recruited in Sweden 
between 1977 and 1999. We defined the high-risk (aggressive) group as patients that 
survived less than 12 months (n=6) and the low-risk (indolent) group as patients that 
survived for more than 192 months (n=12).
Genes differentially expressed between mouse L3 and B6 tumors, p-value 0.01, were 
compared to the human lethality signature using GSEA. (Genes that were differentially 
expressed between the mouse models and did not differentially change between L3 and Lc 
or between B6 and Bc were excluded.) We divided the mouse gene list into those 
corresponding to genes overexpressed in L3 relative to B6 tumors (192 genes), and those 
corresponding to genes overexpressed in B6 compared to L3 (187 genes). The statistical 
significance of enrichment between the mouse query genes and the human target signature 
was computed separately for the group up in L3 tumors and the group up in B6 tumors.
Defining tumor subtypes in human patients
We examined the expression of the 68 genes in the leading-edge luminal origin signature 
(LOLES) in 5 high-quality patient datasets in the Oncomine database22, 26–29, and found 19 
genes to be up-regulated in prostate cancer relative to benign prostate tissue in at least 3 of 
the 5 datasets (Supplementary Fig. S6o, (Supplementary Table S10 . We used the LOLES to 
stratify the 79 primary tumor samples from the Glinsky dataset30 and the 131 primary tumor 
samples from the Taylor dataset22. When multiple probes mapped to a single gene, the probe 
with the highest coefficient of variation was selected to represent the gene. To differentiate 
between aggressive and non-aggressive cases of prostate cancer, an event for the survival 
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analysis was defined as a biochemical recurrence happening within five years. The LOLES 
classified these patients into high-risk and low-risk classes after k-means clustering with the 
kmeans function in R. The difference between these two classes was tested with respect to 
BCR survival time (Kaplan-Meier BCR-free survival curve) and the p-value of this 
difference was computed with a log-rank test. For analysis of the Swedish cohort25, we 
avoided overfitting by excluding patients used to construct the high-risk or low-risk human 
lethality signature (6 high-risk and 12 low-risk samples), resulting in 263 samples.
Pathway analysis
Enrichment of the mouse L3 vs. B6 signature in human biological pathways was evaluated 
by GSEA using pathways collected in the REACTOME52, KEGG53, and BioCarta (http://
www.biocarta.com/genes/allpathways.asp) databases. We mapped mouse genes to human 
orthologs using mouse-human orthologous relations from the Mouse Genome Informatics 
database (http://www.informatics.jax.org/), and selected those mapped genes that appeared 
in at least one biological pathway, resulting in 9,945 unique genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
High frequency of prostate basal stem/progenitor cells in sphere formation and tissue 
reconstitution assays. For all analyses, tamoxifen-induced CK5-CreERT2; R26R-YFP/+ mice 
were analyzed at 14 days after tamoxifen treatment. (a) Immunofluorescence staining 
showing co-localization of YFP with CK5 in basal cells (arrowheads) of the anterior 
prostate. (b) Purification of YFP+ basal cells from dissociated prostate tissue by flow 
cytometry. (c) Flow-sorting of YFP+ cells shows that 98.7% are CD49f+, and 8.0% are 
Lin−Sca-1+CD49fhi cells. (d,e) Flow sorting of Lin−Sca-1+CD49fhi cells (panel d, 0.6% of 
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total Lin− cells) shows that 24.4% are YFP+ (e). (f) Quantitation of sphere formation from 
80,000 or 20,000 dissociated prostate cells, showing the number of total spheres as well as 
YFP+ spheres. Each experiment was performed six times, using two replicates each from 
three independent mice; error bars correspond to standard deviation and show variability 
between the six samples. Inset shows epifluorescence detection of YFP expression in 
spheres (arrow). (g) Quantitation of sphere formation from 3,000 dissociated YFP+ cells 
isolated from CK5-CreERT2; R26R-YFP/+ mice at 2 months or 12 months of age. The 
frequencies at these two stages are not statistically different by two sample t-test. (h) Serial 
dilution analysis of purified YFP+ cells in assays of prostate duct formation in renal grafts. 
(i) Extreme limiting dilution analysis of data in (h). (j) YFP fluorescence of a renal graft 
attached to a portion of kidney tissue. (k,l) Hematoxylin-eosin staining of a tissue section 
from a renal graft generated from purified YFP+ basal cells; luminal (lum) and basal (bas) 
cells are indicated (l). (m-o) Analysis of YFP together with CK5 expression in basal cells 
(arrowheads, m), CK18 in luminal cells (arrows, n), and AR (o) in renal grafts. Scale bars in 
a,m-o correspond to 50 microns, in k,l to 100 microns, and in j to 1 mm.
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Figure 2. 
Detection of rare bipotential basal progenitors during prostate regeneration in vivo. (a) 
Lineage-tracing strategy during prostate regeneration of CK5-CreERT2; R26R-YFP/+ mice. 
(b,c) Co-localization of YFP with CK5-expressing basal cells (arrowheads) in regenerated 
CK5-CreERT2; R26R-YFP/+ anterior prostate (b) and dorsolateral prostate (c). (d-f) Most 
YFP+ cells (arrowheads) do not express the luminal marker CK18, although rare 
YFP+CK18+ (arrow, e) and YFP+AR+ (arrow, f) luminal cells can be detected after one 
round of regeneration. (g) Ki67 immunostaining at two days after androgen administration 
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shows that most luminal and some basal cells (arrowhead) undergo proliferation. (h) 
Quantitation of cell proliferation assays during regeneration, showing that 7.4% of basal 
cells (n=510/6,929) and 88.7% of luminal cells (n=6,708/7,565) were BrdU+ after 12 days 
of incorporation; 8.0% of basal cells (n=426/5,326) and 90.1% of luminal cells 
(n=6,945/7,709) were Ki67+ at 2 days of regeneration; and 8.1% of basal cells 
(n=380/4,700) and 85.1% of luminal cells (n=7,094/8,333) were Ki67+ at 4 days of 
regeneration; 3 animals were analyzed for each experiment. See Supplementary Fig. S3 and 
Supplementary Table S1 for additional data. (i) Lineage-tracing strategy during serial 
regression and regeneration. (j-l,n) YFP+ luminal cells (arrows) that co-express AR (k), 
Nkx3.1 (l), and CK18 (n) are more frequently observed after three rounds (j-l) and five 
rounds (n) of serial regeneration. (m) Castration-resistant luminal cells can be detected after 
four rounds of regression. (o) The frequency of luminal cells among total YFP+ cells during 
regeneration in anterior prostate is 0.04% (n=5/11,427, 3 animals) after 1 round, 0.07% 
(n=13/18,025, 5 animals) after 1 round using an alternate protocol, 0.03% (n=3/10,249, 3 
animals) after 1 round in 12-month old mice, 0.6% (n=56/9,129, 3 animals) after 3 rounds, 
and 3.4% (n=303/8,875, 3 animals) after 5 rounds. The 1 round frequencies are not 
statistically different, while p<0.0001 for frequencies of different rounds by χ2 test. See 
Supplementary Fig. S4 and Supplementary Table S1 for additional data. Abbreviations: AP, 
anterior prostate; DLP, dorsolateral prostate. Scale bars in b-g,j-n correspond to 50 microns; 
error bars in h,o correspond to standard deviation and show variability between animals.
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Figure 3. 
Detection of rare bipotential basal progenitors during prostate homeostasis. (a) Time course 
of lineage-tracing analysis in hormonally intact CK5-CreERT2; R26R-YFP/+ mice. (b-d) 
Co-localization of YFP and CK5 in prostate basal cells in mice at 4 months (b), 6 months 
(c), and 12 months (d) of age. (e) Detection of YFP+CK18+ luminal cells (arrow) at 12 
months of age. (f) The frequency of luminal cells among total YFP+ cells during 
homeostasis is 0.02% (n=2/8,848) at 4 months, 0.5% (n=57/10,572) at 6 months, and 3.0% 
(n=227/7,638) at 12 months; 3 animals were analyzed at each time point. p<0.0001 for 
frequencies at different time points by χ2 test. (g) Graphical summary of BrdU incorporation 
analyses during homeostasis; 3 animals were analyzed for each experiment. BrdU 
incorporation frequencies at different time points are not statistically different by χ2 test. See 
Supplementary Table S1 for additional data. (h) Strategy for analyses of cell proliferation at 
three different ages in wild-type C57BL/6 mice. At 2 months, 6 months, or 12 months of 
age, BrdU was administered for 12 days followed by analysis. (i-n) Analysis of co-
localization of BrdU immunostaining with CK5 (i,k,m) or CK18 (j,l,n); arrowheads indicate 
BrdU-positive basal cells, and arrows indicate BrdU-positive luminal cells. Scale bars in b-
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e,i-n correspond to 50 microns; error bars in f,g correspond to standard deviation and show 
variability between animals.
Wang et al. Page 21
Nat Cell Biol. Author manuscript; available in PMC 2013 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Basal cells are a cell type of origin for prostate tumors. (a) Time course for tumor formation 
in hormonally-intact CK5-CreERT2; Ptenflox/flox; R26R-YFP/+ mice. (b-d) Hematoxylin-
eosin staining of anterior prostates showing slight epithelial hyperplasia at 1 month after 
induction (b), low-grade PIN at 3 months after induction (c), and high-grade PIN at 6 
months after induction (d). (e) High-grade PIN in Nkx3.1CreERT2/+; Ptenflox/flox; R26R-
YFP/+ anterior prostate at 3 months after induction. (f-l) Marker analysis of PIN lesions in 
CK5-CreERT2; Ptenflox/flox; R26R-YFP/+ anterior prostate. (f) Phosphorylated Akt (pAkt) 
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can be detected in basal cells at 1 month after induction. (g,h) Ki67 immunoreactivity can be 
detected in basal cells at one month after induction, prior to PIN lesion formation (g), as 
well as at three months after induction (h). (i,j,k) Most transformed cells at three months 
after induction do not express CK5 (i), but instead express CK18 (j) and AR (k). (l) 
CK5+CK18+ intermediate cells (arrowhead) can be detected in PIN lesions at three months 
after induction. (m) Quantitation of basal (CK5+CK18−), luminal (CK5−CK18+), and 
intermediate cells (CK5+CK18+) in YFP+ prostate cells of CK5-CreERT2; Ptenflox/flox; 
R26R-YFP/+ and Nkx3.1CreERT2/+; Ptenflox/flox; R26R-YFP/+ mice at the indicated times 
after induction. Scale bars in b-e correspond to 100 microns, and in f-l to 50 microns.
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Figure 5. 
A luminal origin gene signature that is prognostic for human prostate cancer outcome. (a) 
Scatter-plot of the two main components from a Principal Components Analysis based on 
14,063 genes, capturing 55% (dimension 1) and 21% (dimension 2) of the data variability. 
(b) Scatter-plot without the control samples. Abbreviations: Bc, basal origin control; B3, 
basal origin 3 months post-induction; B6, basal origin 6 months post-induction; Lc, luminal 
origin control; L1, luminal origin 1 month post-induction; L3, luminal origin 3 months post-
induction. (c) GSEA comparison of basal origin “initiation” signature (B3 relative to Bc) to 
luminal “initiation” signature (L1 relative to Lc) shows strong enrichment in both directions. 
(d) GSEA comparison of basal origin “progression” signature (B6 relative to B3) to luminal 
“progression” signature (L3 relative to L1) also shows strong enrichment in both directions. 
(e,f) GSEA shows that genes up-regulated in the L3 versus B6 gene signature are strongly 
enriched in a human signature corresponding to lethality due to prostate cancer (e), but not 
the converse (f). (g) GSEA shows biological pathways significantly enriched in the L3 
versus B6 gene signature; p-value is estimated using 1,000 sample permutations. Pathways 
in red are up-regulated in luminal origin tumors while pathways in blue are up-regulated in 
basal origin tumors. (h,i) Kaplan-Meier analysis shows that the LOLES (corresponding to 
the 68 genes to the left of the dashed line in e) stratifies patients from two independent 
cohorts into groups with different rates of biochemical recurrence (red curve, “luminal-like” 
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group, 37 patients in h, 52 patients in i; blue curve, “non-luminal-like” group, 42 patients in 
h, 79 patients in i). (j) Kaplan-Meier analysis shows that the LOLES stratifies patients from 
the Swedish “watchful waiting” cohort into a “luminal-like” group (red curve, 132 patients) 
and a “non-luminal-like” group (blue curve, 131 patients) with different survival outcomes 
(82 months versus 123 months at 50% survival). (k) C-statistics analysis shows that the 
LOLES improves the prognostic value of Gleason score in the Swedish cohort from 0.76 to 
0.82, with the 95% confidence intervals and p-values shown.
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Figure 6. 
Two models for prostate epithelial lineage relationships and cell of origin for cancer. (a) In a 
conventional lineage hierarchy model, luminal and basal lineages are independently 
maintained by largely unipotent stem/progenitor cells in the normal adult prostate 
epithelium. However, luminal and basal progenitors can generate the other cell type during 
prostate regeneration and tissue homeostasis (dashed lines); in the case of luminal stem/
progenitor cells, it remains unclear whether such bipotentiality (blue dashed line) is 
displayed only by CARNs in the regressed state. In the case of the basal lineage, bipotential 
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stem cells are relatively rare (approximately 0.05%), while basal cells that can display stem 
cell properties in sphere formation and tissue reconstitution assays are more common 
(approximately 4%), and perhaps might correspond to transit-amplifying cells. Oncogenic 
transformation of either luminal or basal cells by inactivation of Pten results in tumors with 
histologically similar luminal phenotypes, but tumors arising from basal cells first undergo 
basal cell proliferation and subsequently luminal differentiation. Tumors may arise from 
stem cells (dark red jagged arrows) or may also be derived from more differentiated cell 
types (light red jagged arrows). (b) In a stochastic progenitor model, basal cells within an 
intact prostate epithelium randomly display stem/progenitor properties at very low 
frequencies (orange), giving rise to luminal cells and being capable of self-renewal. 
(Luminal cells could conceivably follow a similar stochastic progenitor model, but this is 
not shown.) After tissue dissociation, however, the probability of such random basal stem/
progenitor cells may be greatly increased. Oncogenic transformation of normal basal cells 
and/or stochastic basal progenitors leads to luminal differentiation and tumor formation; 
however, it is unlikely that stochastic progenitors represent the sole cell of origin following 
Pten deletion, given the rarity of these progenitors versus the frequency of observed PIN 
lesions.
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